ResearcherHouston MethodistActive in the last 2 years
Ashish Saharia
Matched on ORCID iD 0000-0001-5366-8432; OpenAlex author ID A5085072672. Sources: OpenAlex.
Their work
- Papers
- 4 (first author 1, last author 0)
- Trials
- 0
- Grants
- 0
- Labs led
- 0
- Collaborators
- 8
2019: 1 paper · 2020: 2 papers · 2021: none · 2022: none · 2023: none · 2024: none · 2025: none · 2026: 1 paper
Papers 4
- Neoadjuvant Therapy and Pancreatic Cancer Resection Outcomes: A Retrospective Analysis at a Quaternary Care Center. Co-author DOI 10.1016/j.jss.2026.02.012↗
- Is Surgery-first Still a Reasonable Option in the Era of Neoadjuvant Chemotherapy for Resectable Pancreatic Cancer? Co-author DOI 10.1097/coc.0000000000000661↗
- Commentary on Neoadjuvant Versus Surgery First Approach in Resectable Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1097/coc.0000000000000743↗
- Promising new treatments for pancreatic cancer in the era of targeted and immune therapies. First author PMID 31598392↗
Closest collaborators
The 8 strongest of 8 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- Maen Abdelrahim · 4 shared papers, 2019–2026 · strength 0.59
- Paper Neoadjuvant Therapy and Pancreatic Cancer Resection Outcomes: A Retrospective Analysis at a Quaternary Care Center. DOI 10.1016/j.jss.2026.02.012↗
- Paper Commentary on Neoadjuvant Versus Surgery First Approach in Resectable Pancreatic Ductal Adenocarcinoma. DOI 10.1097/coc.0000000000000743↗
- Paper Is Surgery-first Still a Reasonable Option in the Era of Neoadjuvant Chemotherapy for Resectable Pancreatic Cancer? DOI 10.1097/coc.0000000000000661↗
- Kirk Heyne · 4 shared papers, 2019–2026 · strength 0.59
- Paper Neoadjuvant Therapy and Pancreatic Cancer Resection Outcomes: A Retrospective Analysis at a Quaternary Care Center. DOI 10.1016/j.jss.2026.02.012↗
- Paper Commentary on Neoadjuvant Versus Surgery First Approach in Resectable Pancreatic Ductal Adenocarcinoma. DOI 10.1097/coc.0000000000000743↗
- Paper Is Surgery-first Still a Reasonable Option in the Era of Neoadjuvant Chemotherapy for Resectable Pancreatic Cancer? DOI 10.1097/coc.0000000000000661↗
- Ahmed Elaileh · 3 shared papers, 2019–2026 · strength 0.45
- Paper Neoadjuvant Therapy and Pancreatic Cancer Resection Outcomes: A Retrospective Analysis at a Quaternary Care Center. DOI 10.1016/j.jss.2026.02.012↗
- Paper Is Surgery-first Still a Reasonable Option in the Era of Neoadjuvant Chemotherapy for Resectable Pancreatic Cancer? DOI 10.1097/coc.0000000000000661↗
- Paper Promising new treatments for pancreatic cancer in the era of targeted and immune therapies. PMID 31598392↗
- Kelvin Allenson · 1 shared paper, 2026 · strength 0.23
- Nestor F. Esnaola · 1 shared paper, 2026 · strength 0.23
- Ahmed Osama Gaber · 1 shared paper, 2026 · strength 0.23
- Ashton Anthony Connor · 1 shared paper, 2026 · strength 0.23
- Youssef E. Dib · 1 shared paper, 2026 · strength 0.23
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.